← Eichor
Study identifier: NCT06806462 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Biomolecular Markers of Bone Metastasis

Condition: Bone Metastasis  ·  Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

PhaseNA
Planned participants160
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to characterize the biomolecular profile of bone metastases to define the predisposing profiles of bone metastasis, in patients with breast or lung or renal carcinomas or of the gastroenteric or prostate tract with bone metastasis. The main question it aims to answer is: Is it possible to predict the progression of bone metastasis by identifying biomarkers as risk factors for bone metastasis?

This description comes directly from the study's public registry record.

Talk to the study team

Andrea Sambri, MD  ·  0512142680  ·  andrea.sambri@aosp.bo.it

Always discuss trial participation with your own doctor first.

Locations (1)

IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, Bologna, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06806462